FY2024 EPS Estimates for Personalis Lowered by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL) – Stock analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Personalis in a note issued to investors on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($1.37) per share for the year, down from their previous forecast of ($1.01). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Personalis’ Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.46) EPS and FY2027 earnings at ($0.04) EPS.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The company had revenue of $25.71 million for the quarter, compared to analysts’ expectations of $20.67 million. During the same period in the previous year, the business posted ($0.51) EPS.

PSNL has been the subject of several other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $7.25 target price on shares of Personalis in a research report on Thursday, November 7th. BTIG Research lifted their price objective on shares of Personalis from $5.50 to $7.00 and gave the company a “buy” rating in a report on Friday, August 16th.

Personalis Trading Up 6.3 %

PSNL stock opened at $5.23 on Monday. The business’s fifty day moving average price is $5.12 and its 200 day moving average price is $3.42. Personalis has a 12-month low of $1.00 and a 12-month high of $7.20. The company has a market capitalization of $277.61 million, a PE ratio of -3.11 and a beta of 1.94.

Institutional Investors Weigh In On Personalis

Several large investors have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio purchased a new position in shares of Personalis in the 1st quarter valued at about $29,000. nVerses Capital LLC purchased a new position in Personalis in the third quarter worth approximately $40,000. Virtu Financial LLC acquired a new position in Personalis during the 1st quarter worth approximately $41,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in Personalis by 42.5% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after acquiring an additional 4,504 shares in the last quarter. Finally, International Assets Investment Management LLC increased its position in shares of Personalis by 438.0% in the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after purchasing an additional 17,082 shares during the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.